|Ms. Rachel K. King||Pres, CEO & Director||772.42k||N/A||1959|
|Mr. Brian M. Hahn||CFO & Sec.||458.38k||N/A||1974|
|Dr. John L. Magnani||Sr. VP of Research, Chief Scientific Officer & Director||529.58k||N/A||1953|
|Dr. Helen M. Thackray||Sr. VP of Clinical Devel. & Chief Medical Officer||577.27k||N/A||1968|
|Mr. Henry Flanner||VP of Technical Operations||N/A||N/A||N/A|
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.